Role of IMP3 Expression in Colorectal Carcinoma: An Immunohistochemical Study

NCT05601388 | Unknown

• 1 other identifier: Soh-Med-22-09-16
• Study Type: observational
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

Colorectal carcinoma (CRC) is the third most common malignancy worldwide. In Egypt, the relative frequency of CRC is about 9-12% with high male predominance 3:1. The high mortality rates associated with CRC is reflective of several factors including: the lack of apparent symptoms in the early stages and the absence of cancer prevention strategies in developing countries. Insulin-like growth factor II m-RNA-binding protein 3 (IMP3) is a member of the IMP family which plays a key role in the transfer and stabilization of mRNA, cell growth, and migration during embryogenesis. IMP3 has gained considerable interest as a cancer-associated protein. Previous studies strongly suggest that IMP3 may represent a valuable prognostic marker in human cancer. Its overexpression has been reported in a variety of human types of cancer, including lung cancer, colon cancer, pancreatic cancer, gastric cancer, liver cancer, and breast cancer

Conditions

Colorectal Cancer

Outcome Measures

Primary Outcomes (1)

• evaluate the immunohistochemical (IHC) expression of IMP3 in CRC and to correlate its expression with some known clinicopathological parameters.

  IHC

  4 months

Eligibility Criteria

• Sex: all
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Sixty specimens of CRC will be obtained from patients who will undergo colectomy in General Surgery Department of Sohag Faculty of Medicine according to local Ethical Committee regulations, to be examined in the Pathology Laboratory of the same faculty. From October 2022, till completing the sample size.

You may qualify if:

• Patients with CRC and will be underwent surgery.

You may not qualify if:

• \- Patients received pre-operative chemotherapy or radiotherapy.
• Patients with insufficient clinical data.

Sponsors & Collaborators

• Sohag University: lead

Study Sites (1)

Faculty of Medicine

Sohag, Egypt

RECRUITING

MeSH Terms

Conditions

Colorectal Neoplasms

Condition Hierarchy (Ancestors)

Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases

Central Study Contacts

Nagwa Ahmed, Lecture

CONTACT

01017415996; nagwa.sadek@med.sohag.edu.eg

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Target Duration: 5 Months
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Lecturer at Pathology Department, Faculty of Medicine

Study Record Dates

• First Submitted: October 27, 2022
• First Posted: November 1, 2022
• Study Start: October 1, 2022
• Primary Completion: March 1, 2023
• Study Completion: June 1, 2023
• Last Updated: November 1, 2022

Record last verified: 2022-10

Locations

EG (1)